Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Sangamo Therapeutics (SGMO) over the last 16 years, with Q3 2025 value amounting to $3.5 million.

  • Sangamo Therapeutics' Change in Accured Expenses rose 26094.67% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.0 million, marking a year-over-year increase of 7892.61%. This contributed to the annual value of -$14.2 million for FY2024, which is 1165.48% down from last year.
  • Per Sangamo Therapeutics' latest filing, its Change in Accured Expenses stood at $3.5 million for Q3 2025, which was up 26094.67% from -$3.5 million recorded in Q2 2025.
  • Over the past 5 years, Sangamo Therapeutics' Change in Accured Expenses peaked at $16.1 million during Q3 2022, and registered a low of -$8.6 million during Q1 2023.
  • Over the past 5 years, Sangamo Therapeutics' median Change in Accured Expenses value was -$1.4 million (recorded in 2021), while the average stood at -$888157.9.
  • Per our database at Business Quant, Sangamo Therapeutics' Change in Accured Expenses surged by 121071.92% in 2022 and then tumbled by 131122.81% in 2025.
  • Sangamo Therapeutics' Change in Accured Expenses (Quarter) stood at -$3.0 million in 2021, then soared by 231.7% to $3.9 million in 2022, then crashed by 291.29% to -$7.5 million in 2023, then increased by 2.03% to -$7.3 million in 2024, then soared by 148.32% to $3.5 million in 2025.
  • Its Change in Accured Expenses stands at $3.5 million for Q3 2025, versus -$3.5 million for Q2 2025 and $4.2 million for Q1 2025.